

Cover Sheet

Trust Board Meeting in Public: Wednesday 9 November 2022

TB2022.103

Title: Integrated Assurance Committee Report

Status: For Information
History: Regular Reporting

Board Lead: Trust Chair
Author: Laura Lauer, Deputy Head of Corporate Governance
Confidential: No
Key Purpose: Assurance

Integrated Assurance Committee Report

1. Purpose

- 1.1. As a Committee of the Trust Board, the Integrated Assurance Committee provides a regular report to the Board on the main issues raised and discussed at its meetings.
- 1.2. Since the last report to the Board held in public, the Integrated Assurance Committee had met on 12 October 2022.
- 1.3. Under its terms of reference, the Integrated Assurance Committee is responsible for reporting to the Board items discussed, actions agreed and issues to be referred to the Board, indicating the extent to which the Committee was able to take assurance from the evidence provided and where additional information was required.

2. Key Areas of Discussion

- 2.1. The Committee sought assurance that the Trust was continuing to effectively manage operational pressures and performance at local level and influence the system through its partnership working.
- 2.2. Discussion focused on the Trust's management of risks in relation to operational performance. The Committee was able to take assurance from its review of the cross-divisional improvement programmes. It heard about the Trust's efforts to support and retain staff.
- 2.3. The Committee examined the complexities faced by the Trust in the management risk, much of which was at system-level. It was satisfied that the Trust was committed to identifying and reducing risk wherever it could.

Integrated Performance Report

- 2.4. The Committee received this regular report on performance across operational, quality, workforce, digital and financial metrics.
- 2.5. Discussion focused on harm reduction and the integration of data sources to enable more effective intervention. The Committee was particularly concerned with target metrics and timescales.

H2 Elective and Cancer Plan 2022/23 Update

- 2.6. The Committee was briefed on the Trust's position against national requirements.
- 2.7. A summary of action being taken to clear 104- and 78-week waits was provided; this included work to increase theatre capacity and address shortages in the Trust's anaesthetic workforce.

- 2.8. The Committee noted the challenges within the Integrated Care System and the Trust's efforts to promote collaborative working across the system to more effectively balance the workload.

Quality and Performance Reviews

- 2.9. The Committee received an update on the Integrated Quality Improvement Plan and noted that work was well underway. The Trust's Commissioning for Quality and Innovation (CQUIN) scheme performance for the first quarter of 2022/23 (Q1) was noted.
- 2.10. The Trust's use of Quality Impact Assessments to inform decision-making was noted and supported.
- 2.11. The Committee received a report of the Divisional Performance Reviews for Q1; these demonstrated collective oversight of performance. An additional review on Quality – Clinical Governance was received.

Other Regular Reporting

- 2.12. The Committee received the Annual Clinical Effectiveness Report. Regular update reports on infection prevention and control matters, SIRIs and Never Events, and the Board Assurance Framework and Corporate Risk Register were received.

Deep Dive

- 2.13. Following the meeting, members were briefed on the work of the Data and Analytics Team and how various projects supported the Trust's Digital Plan.

3. Key Actions

- 3.1. The Committee agreed to review assurance on estates compliance and medicines reconciliation at its next meeting.

4. Recommendations

- 4.1. The Trust Board is asked to:
- **note** the Integrated Assurance Committee's report to the Board from its meeting held on 12 October 2022.